ISIC C21 · China · 8 publishers
Pharmaceuticals in China
229 verified figures for China, covering 112 indicators from 8 primary sources. Every figure links to the report it came from.
China compared
| Measure | China | World | Highest country |
|---|---|---|---|
| Alzheimer's disease drug trial starts | 46China · 1 Jan 2023 to 27 Sep 2026 | 269World · 1 Jan 2023 to 27 Sep 2026 | 128United States · 1 Jan 2023 to 27 Sep 2026 |
| Antibody-drug conjugate trial starts | 638China · 1 Jan 2023 to 27 Sep 2026 | 1,225World · 1 Jan 2023 to 27 Sep 2026 | China is highest |
| Autoimmune cell therapy and T-cell engager trial starts | 185China · 1 Jan 2023 to 27 Sep 2026 | 300World · 1 Jan 2023 to 27 Sep 2026 | China is highest |
| Cardiometabolic RNA and next-generation lipid drug trial starts | 35China · 1 Jan 2023 to 27 Sep 2026 | 128World · 1 Jan 2023 to 27 Sep 2026 | 90United States · 1 Jan 2023 to 27 Sep 2026 |
| GLP-1, incretin multi-agonist and amylin trial starts | 178China · 1 Jan 2023 to 27 Sep 2026 | 798World · 1 Jan 2023 to 27 Sep 2026 | 378United States · 1 Jan 2023 to 27 Sep 2026 |
| Gene editing trial starts | 54China · 1 Jan 2023 to 27 Sep 2026 | 133World · 1 Jan 2023 to 27 Sep 2026 | China is highest |
The short version
Key takeaways
Market size and output 5
- Cardiometabolic RNA and next-generation lipid drug trial starts in China were 12 in 2025 (ClinicalTrials.gov). ClinicalTrials.gov ↗ T1 Official
- Cumulative negotiated drug sales during agreement period in China was more than 510 billion CNY in January 2018 – October 2024 (State Council). State Council ↗ T1 Official
- Alzheimer's disease drug trial starts in China were 16 in 2025 (ClinicalTrials.gov). ClinicalTrials.gov ↗ T1 Official
- Antibody-drug conjugate trial starts in China were 177 in 2025 (ClinicalTrials.gov). ClinicalTrials.gov ↗ T1 Official
- Autoimmune cell therapy and T-cell engager trial starts in China were 76 in 2025 (ClinicalTrials.gov). ClinicalTrials.gov ↗ T1 Official
Other measures 5
- Innovative drug licensing-out upfront payment value in China was 7 billion USD in 2025 (MOFCOM). MOFCOM ↗ T1 Official
- Innovative drug out-licensing deal value in China was more than 130 billion USD in 2025 (NHSA). NHSA ↗ T1 Official
- Approved Class 1 innovative drugs in China were 76 in 2025 (NHSA). NHSA ↗ T1 Official
- Approved innovative drugs with new targets or mechanisms in China were 11 in 2025 (NHSA). NHSA ↗ T1 Official
- Bioequivalence trials in China were 2,218 in 2025 (NHSA). NHSA ↗ T1 Official
The complete table
Pharmaceuticals data for China
Every row links to its own page with the full source, verbatim quote and citation.
229 data points across 112 indicators. Each line shows the latest value; open a line for earlier periods and forecasts.
IndicatorPeriodValueSourceType
Alzheimer's disease drug trial starts+6 more1 Jan 2023 to 27 Sep 202646ClinicalTrials.govT12026actual→
Antibody-drug conjugate trial starts+6 more1 Jan 2023 to 27 Sep 2026638ClinicalTrials.govT12026actual→
Approved innovative drugs designated as breakthrough therapies+1 more202413State CouncilT12024actual→
Autoimmune cell therapy and T-cell engager trial starts+6 more1 Jan 2023 to 27 Sep 2026185ClinicalTrials.govT12026actual→
Cardiometabolic RNA and next-generation lipid drug trial starts+6 more1 Jan 2023 to 27 Sep 202635ClinicalTrials.govT12026actual→
Clinical trial country use share+2 more202315%IQVIA2023actual→
Domestic first-in-class drug approvals+1 more20254MOFCOMT12025actual→
Domestic innovative biological product approvals+1 more202521NHSAT12025actual→
Domestic innovative chemical drug approvals+1 more202538NHSAT12025actual→
Domestic innovative drug approvals (half year)+1 moreJanuary–June 202631MOFCOMT12026actual→
Domestic share of approved innovative biological products+1 more202591.3%NHSAT12025actual→
Domestic share of approved innovative chemical drugs+1 more202580.8%MOFCOMT12025actual→
Drugs in commercial health insurance innovative drug catalog+1 moreas of 7 Dec 202519State CouncilT12025actual→
Drugs removed from national reimbursement drug list+1 more202529NHSAT12025actual→
First-in-class drug approvals+8 more202511NHSAT12025actual→
Gene editing trial starts+6 more1 Jan 2023 to 27 Sep 202654ClinicalTrials.govT12026actual→
GLP-1, incretin multi-agonist and amylin trial starts+6 more1 Jan 2023 to 27 Sep 2026178ClinicalTrials.govT12026actual→
Imported innovative biological product approvals+1 more20252MOFCOMT12025actual→
Imported innovative chemical drug approvals+1 more20259NHSAT12025actual→
Inflammatory bowel disease drug trial starts+6 more1 Jan 2023 to 27 Sep 2026101ClinicalTrials.govT12026actual→
Innovative biological product approvals+1 more202523NHSAT12025actual→
Innovative drug approvals+4 more202576MOFCOMT12025actual→
Innovative drug approvals (half year)+1 moreJanuary–June 202638MOFCOMT12026actual→
Innovative drug out-licensing deal count+3 more2025157MOFCOMT12025actual→
Innovative drug out-licensing deal value+4 more2025130 billion USDNHSAT12025actual→
Innovative drug out-licensing deal value (half year)+2 moreJanuary–June 2026100 billion USDState CouncilT12026actual→
Innovative drugs added to national health insurance catalog+1 moreas of 7 Dec 202550State CouncilT12025actual→
Innovative traditional medicine approvals+1 more20256MOFCOMT12025actual→
KRAS and RAS inhibitor trial starts+6 more1 Jan 2023 to 27 Sep 202691ClinicalTrials.govT12026actual→
New drug clinical trials+1 more20252,997NHSAT12025actual→
Newly added drugs in national reimbursement drug list+2 moreas of 7 Dec 2025114SCIOT12025actual→
Newly added drugs in national reimbursement drug list (annual)+1 more2025114NHSAT12025actual→
Oncology bispecific antibody trial starts+6 more1 Jan 2023 to 27 Sep 2026489ClinicalTrials.govT12026actual→
Pediatric medicine approvals+2 more2024106NMPAT12024actual→
Pharmaceutical export delivery value growth (half year)+1 moreJanuary–June 20269%MOFCOMT12026actual→
Pharmaceutical value-added industrial output growth (half year)+1 moreJanuary–June 20266.4%MOFCOMT12026actual→
Radioligand therapy trial starts+6 more1 Jan 2023 to 27 Sep 202675ClinicalTrials.govT12026actual→
Rare disease medicine approvals+2 more202455NMPAT12024actual→
Reimbursement drug list total drugs+3 moreas of 7 Dec 20253,253SCIOT12025actual→
Share of global biopharmaceutical pipeline+1 more202530%State CouncilT12025actual→
Showing the 40 best-covered of 112 indicators. Download all 229 rows as CSV
Pharmaceuticals in China by topic
- Pharmaceuticals · 70 records46Clinical trial starts in China
- Pharmaceuticals · 70 records38New drug approvals in China
- Pharmaceuticals · 16 records199Reimbursement list additions in China
- Pharmaceuticals · 11 records2,218Clinical trial registrations in China
- Pharmaceuticals · 10 records3,253Drugs on reimbursement lists in China
- Pharmaceuticals · 3 records15%Clinical trial locations by country in China
Primary documents
Sources
| Document | Publisher | Authority tier | Published | Accessed | Locator | Data points |
|---|---|---|---|---|---|---|
| ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China. | 1 |
| 2025年我国批准创新药76个 对外授权超千亿美元 Press release | MOFCOM | T1 Official | — | 17 Sep 2026 | 2025年我国批准创新药76个 对外授权超千亿美元 | 18 |
| 上半年我国创新药对外技术授权交易额创新高 Press release | MOFCOM | T1 Official | — | 17 Sep 2026 | 上半年我国创新药对外技术授权交易额创新高 | 7 |
| 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录 Press release | NHSA | T1 Official | 28 Nov 2024 | 17 Sep 2026 | 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录 | 12 |
| 国新办举行国务院政策例行吹风会介绍健全全周期全渠道药品价格形成机制有关情况 Press release | NHSA | T1 Official | — | 17 Sep 2026 | 大众新闻大众日报记者提问; 红星新闻记者提问 | 4 |
| 我国上半年创新药对外授权交易额超千亿美元 Press release | NHSA | T1 Official | — | 17 Sep 2026 | 今年38个1类创新药已获批上市 11款新靶点、新机制药均为国产; 我国上半年创新药对外授权约1100亿美元 创历史新高; 11款新靶点新机制创新药涵盖哪些治疗领域 | 11 |
| 从“0”到“1”创新能力增强 我国新药研发热度持续攀升 Press release | NHSA | T1 Official | — | 17 Sep 2026 | 试验包括新药临床试验和生物等效性试验; 新药临床试验近六成 其中超七成是创新药; 从“0”到“1”创新能力增强 我国新药研发热度持续攀升 | 12 |
| 国家医保局 人力资源社会保障部印发2025年版国家基本医疗保险、生育保险和工伤保险药品目录和商业健康保险创新药品目录 Press release | NHSA | T1 Official | — | 17 Sep 2026 | 国家医保局 人力资源社会保障部印发2025年版国家基本医疗保险、生育保险和工伤保险药品目录和商业健康保险创新药品目录 | 6 |
| 创新高！去年我国批准创新药76个 对外授权破千亿美元 Press release | NHSA | T1 Official | — | 17 Sep 2026 | 创新高！去年我国批准创新药76个 对外授权破千亿美元 | 16 |
| Measures facilitate approval of 48 first-in-class innovative drugs Press release | NMPA | T1 Official | — | 17 Sep 2026 | Measures facilitate approval of 48 first-in-class innovative drugs | 11 |
| China approves 48 innovative drugs in 2024 Press release | NMPA | T1 Official | — | 17 Sep 2026 | China approves 48 innovative drugs in 2024 | 6 |
| China updates national medical insurance catalog, adds 114 new drugs Press release | SCIO | T1 Official | — | 17 Sep 2026 | China updates national medical insurance catalog, adds 114 new drugs | 4 |
| Measures facilitate approval of 48 first-in-class innovative drugs Press release | State Council | T1 Official | — | 17 Sep 2026 | Measures facilitate approval of 48 first-in-class innovative drugs | 11 |
| 2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药_政策解读_中国政府网 Press release | State Council | T1 Official | — | 17 Sep 2026 | 7年累计将835种药品新增进入目录; 2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药; “全球新”的创新药有38种，创历年新高 | 10 |
| Value of China's innovative drug out-licensing deals hit new high in H1 Press release | State Council | T1 Official | — | 17 Sep 2026 | Value of China's innovative drug out-licensing deals hit new high in H1 | 4 |
| China updates national medical insurance catalog, adds 114 new drugs Press release | State Council | T1 Official | — | 17 Sep 2026 | China updates national medical insurance catalog, adds 114 new drugs | 4 |
| 全面深化监管改革 缩短临床试验审评审批时限——加快创新药和医疗器械上市_政策解读_中国政府网 Press release | State Council | T1 Official | — | 17 Sep 2026 | 大力支持产业创新; 更好满足临床急需 | 2 |
| China to expand health insurance coverage for innovative drugs Press release | State Council | T1 Official | — | 17 Sep 2026 | China to expand health insurance coverage for innovative drugs | 6 |
| 2025 NMPA Approvals: China Clears Record Number of New Drugs Press release | DIA | T2 Official | — | 17 Sep 2026 | Established Modalities Maintain a Larger Presence; The Cancer Sector Continues to Attract the Most Players; Domestic Players Account for Most of China’s Approvals | 11 |
| Rethinking Clinical Trial Country Prioritization Press release | IQVIA | T3 Research | — | 15 Sep 2026 | Key findings:; Country utilization is heavily consolidated in U.S., China and Western European countries | 3 |
| Global Medicine Use Trends 2026 Press release | IQVIA | T3 Research | — | 15 Sep 2026 | Report Summary: | 1 |
Report snapshots are retained internally for verification only and are never redistributed. Where a figure comes from a paywalled report, only the number published in its public summary is recorded.
All 229 collected records for China are published as verified.
Cite & reuse
Cite this page
Data on this page is published under CC BY 4.0. You may reuse it, including commercially, provided you attribute it. Each figure's own page carries APA, MLA, Chicago and BibTeX citations naming its original publisher.
StatOrigin. (2026). Pharmaceuticals in China: statistics. Retrieved from https://statorigin.org/industries/pharmaceuticals/china